Published Date: 16 Jul 2025
A Flinders University study shows that bowel cancer survivors face an elevated risk of developing multiple primary cancers (MPCs)—for prostate, lung, breast and blood cancer.
Read Full NewsFormer UK prime minister Rishi Sunak has called for a targeted prostate cancer screening program for men most at high risk of the disease, reviving a national debate on how to save more lives and tackle health inequalities ...
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed ...
About half of women over 40 have dense breasts. The denser the breast tissue, the more difficult it is to spot cancer on a standard mammogram. Having dense breast tissue can make it harder to detect cancer and sometimes leads ...
Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients—and found a potential way to overcome that resistance.
1.
Pickleball program boosts health and wellness for cancer survivors, study finds
2.
A video animation guide to assist young people who are fatigued from cancer.
3.
Is Exercise an Effective Treatment for Prostate Cancer?
4.
High resolution ultrasound could enable faster prostate cancer diagnosis
5.
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
1.
Unveiling the Hidden Benefits of Lymphedema Treatment
2.
Bridging the Global Divide: Enhancing Psychosocial Care for Cancer Survivors Across Income Settings
3.
Colon cancer: Risk factors, warning signs and treatment options
4.
Exploring the Normal Range of Monocytes: A Comprehensive Guide
5.
Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation